National survey on continuous and extended infusions of antibiotics

American Journal of Health-System Pharmacy

Volumn 69, Issue 21, 2012, Pages 1895-1904

  George, Jomy M ^a   Colton, Benjamin J ^b   Rodvold, Keith A ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b Resurrection Health Care   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CLAVULANATE POTASSIUM PLUS TICARCILLIN; IMIPENEM; MEROPENEM; OXACILLIN PLUS NAFCILLIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; DRUG INFUSION; DRUG USE; EXTENDED DRUG INFUSION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; PHARMACIST; PHARMACIST ATTITUDE; PRIORITY JOURNAL;

EID: 84868609531     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110562     Document Type: Article

References (31)

1. Curcio L. Optimal dosage regimen for penicillins: bolus or continuous infusion? J Antimicrob Chemother. 1979; 5:503-9. (Pubitemid 10235170)
2. Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26:1-10.
3. Kasiakou SK, Lawrence KR, Choulis N et al. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs. 2005; 65:2499-511. (Pubitemid 41697317)
4. Burgess DS, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/ tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther. 2002; 24:1090-104. (Pubitemid 34833232)
5. Roberts JA, Paratz J, Paratz E et al. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007; 30:11-8. (Pubitemid 46874893)
6. Roberts JA, Lipman J, Blot S et al. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care. 2008; 14:390-6.
7. Moriyama B, Henning SA, Childs R et al. High-dose continuous infusion β-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother. 2010; 44:929-35.
8. DeRyke CA, Kuti JL, Mansfield D et al. Pharmacoeconomics of continuous versus intermittent infusion of piperacillintazobactam for the treatment of complicated intraabdominal infections. Am J Health-Syst Pharm. 2006; 63:750-5.
9. Wang D. Experience with extendedinfusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii.Int J Antimicrob Agents. 2009; 33:290-1.
10. Grant EM, Kuti JL, Nicolau DP et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillintazobactam program in a large community teaching hospital. Pharmacotherapy.2002; 22:471-83. (Pubitemid 34270031)
11. Richerson MA, Ambrose PG, Bui KQ et al. Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered as either continuous or intermittent infusion with once-daily gentamicin. Infect Dis Clin Pract. 1999; 8:195-200. (Pubitemid 29202945)
12. Lodise J, Thomas P, Lomaestro B et al. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44:357-63. (Pubitemid 46147617)
13. Chuck S, Raber S, Rodvold K et al. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis. 2000; 30:433-9. (Pubitemid 30205284)
14. Society of Infectious Diseases Pharmacists. What is SIDP? www.sidp.org (accessed 2011 Jun 6).
15. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat.1979; 6:65-70.
16. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health. 1996; 86:726-8. (Pubitemid 26145488)
17. Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med. 1991; 91(suppl 2):S86-9.
18. Yost RJ, Cappelletty DM, for the RECEIPT Study group. The Retrospective Cohort of Extended-Infusion Piperacillin- Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy. 2011; 31:767-75.
19. Kasiakou SK, Sermaides GJ, Michalopoulos A et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005; 5:581-9. (Pubitemid 41196757)
20. Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008; 36:1089-96. (Pubitemid 351482655)
21. Georges B, Conil JM, Cougot P et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther. 2005; 43:360-9. (Pubitemid 41078996)
22. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther.2000; 22:66-75. (Pubitemid 30091424)
23. Nicolau DP, McNabb J, Lacy MK et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents. 2001; 17:497-504. (Pubitemid 32492970)
24. Lau WK, Mercer D, Itani KM et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intraabdominal infection. Antimicrob Agents Chemother. 2006; 50:3556-61. (Pubitemid 44684865)
25. Hanes SD, Wood GC, Herring V et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg. 2000; 179:436-40.
26. James J, Palmer S, Levine D et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother. 1996; 40:696-700. (Pubitemid 26071537)
27. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001; 45:2460-7. (Pubitemid 32801896)
28. Angus BJ, Smith MD, Suputtamongkol Y et al. Pharmacokinetic- pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol.2000; 50:184-91.
29. Mouton J, Vinks A, Punt N. Pharmaco-kinetic- pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother. 1997; 41:733-8. (Pubitemid 27150521)
30. Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with gram-negative bacilli bacteraemia. J Pharm Pharmacol. 2002; 54:1693-6. (Pubitemid 36018820)
31. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994; 38:931-6. (Pubitemid 24150817)